Zyprexa IM Manufacturing Issues To Be Discussed By FDA, Lilly March 15

12 Mar 2001

• By The Pink Sheet

Lilly hopes to be ready for a re-inspection of its intramuscular Zyprexa production facility in mid-May, ahead of the late June user fee deadline for a decision on the new formulation of the antipsychotic.

Zyprexa IM Manufacturing Issues To Be Discussed By FDA, Lilly March 15

More from Archive

More from Pink Sheet